Oral News and Research

RSS

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Experimental drug NU-9 - a small molecule compound approved by the U.S. Food and Drug Administration (FDA) for clinical trials for the treatment of amyotrophic lateral sclerosis (ALS) - improves neuron health in animal models of Alzheimer's disease, according to a new Northwestern University study.

8 Apr 2025

Powerful new tool promises major advances in cancer treatment

New Australian technology is set to transform the way that gastrointestinal cancers are detected and treated with precise, minimally invasive surgery.

8 Apr 2025

Beckman Coulter Life Sciences launches safer, Next-Generation Basophil Activation Test to improve, expedite allergy research

Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, introduces the Next-Generation Basophil Activation Test (BAT) for research use only to more effectively characterize food allergies without exposure to potentially harmful allergens.

From Beckman Coulter Life Sciences - Flow Cytometry 8 Apr 2025

New quantum technology set to revolutionize gastrointestinal cancer detection and treatment

New Australian technology is set to transform the way that gastrointestinal cancers are detected and treated with precise, minimally invasive surgery.

7 Apr 2025

$Diet and exercise habits in your 60s linked to lower fracture and heart death risk$

Diet and exercise habits in your 60s linked to lower fracture and heart death risk

A long-term study in older adults links higher-quality diets to lower risks of hip fracture and cardiovascular death. Researchers suggest that framing bone health through heart disease awareness may better engage men in preventive action.

7 Apr 2025

Breakthrough protein offers new hope for pulmonary sarcoidosis treatment

Pulmonary sarcoidosis is a lung disease characterized by granulomas-tiny clumps of immune cells that form in response to inflammation.

7 Apr 2025

Research uncovers root cause of gland damage in Sjögren's syndrome

Sjögren's syndrome is a chronic autoimmune disorder that affects millions worldwide, especially women, causing unrelenting dryness of the mouth and eyes.

7 Apr 2025

New approach to combat influenza and herpes with bean-based gum

In today's interconnected world, infectious diseases pose an escalating threat, as demonstrated by the coronavirus pandemic and outbreaks of H1N1, SARS, Ebola, Zika, and H5N1 (bird flu) viruses-all of which have had significant global health and economic impacts.

4 Apr 2025

Innovative oral vaccine strategy combats intestinal pathogens

The issue of intestinal bacteria is a complex one. On the one hand, we are dependent on the microorganisms because they are the ones that digest the food in our intestine.

4 Apr 2025

Hormonal contraceptives linked to higher postpartum depression risk

Researchers investigate whether the use of hormonal contraception increases the risk of postpartum depression.

4 Apr 2025

Rutgers researchers develop promising new oral antiviral for COVID-19

Rutgers Health researchers have developed an oral antiviral drug candidate for COVID-19 that could overcome major limitations of Paxlovid, currently the most prescribed oral treatment.

3 Apr 2025

Sweetener saccharin revives old antibiotics by breaking bacterial defences

Saccharin destabilizes bacterial membranes and interferes with DNA replication, causing lysis and impairing virulence traits. The sweetener also re-sensitizes multidrug-resistant pathogens to antibiotics and disrupts stubborn biofilms.

3 Apr 2025

Gut bacteria may reduce the effectiveness of common medications

A new study, published today in Nature Chemistry by researchers from the University of Pittsburgh and Yale University, shows how common gut bacteria can metabolize certain oral medications that target cellular receptors called GPCRs, potentially rendering these important drugs less effective.

3 Apr 2025

New data on use of EndoZip™ to treat obese patients be presented at leading global medical conferences

Nitinotes, developer of EndoZip™, a fully automated endoscopic suturing system aimed at treating obesity, today announced that clinical research on the EndoZip™ system will be presented at upcoming leading international medical conferences.

3 Apr 2025

Gut microbiome interventions could stop type 1 diabetes in its tracks

Researchers at The University of Queensland have found improving the function of the gut microbiome may delay the onset of type 1 diabetes (T1D).

2 Apr 2025

WHO releases first reports on shortages in fungal disease treatments and diagnostics

The World Health Organization (WHO) today published its first-ever reports addressing the critical lack of medicines and diagnostic tools for invasive fungal diseases, showing the urgent need for innovative research and development (R&D) to close these gaps.

2 Apr 2025

Study identifies key predictor of stroke and dementia

A research team from the University of Minnesota Medical School has identified a strong predictor of ischemic stroke and dementia, a discovery that could lead to improved patient outcomes.

1 Apr 2025

Common medicines contain hidden gluten and soy, study finds

A Portuguese study found that over half of paracetamol-based painkillers and a quarter of ibuprofen liquids contain gluten or soy-derived excipients, posing risks for allergy-sensitive individuals.

1 Apr 2025

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Merck, known as MSD outside of the United States and Canada, today announced the first presentation of results from the Phase 3 ZENITH trial evaluating WINREVAIR™ (sotatercept-csrk) compared to placebo in adults with pulmonary arterial hypertension (PAH, Group 1 PH) WHO* functional class (FC) III or IV at high risk of mortality who were on maximum tolerated background PAH therapy. At a median follow-up of 10.6 months (range, 0.3-26.1), WINREVAIR reduced the relative risk of major morbidity and mortality events (the composite of all-cause death, lung transplantation and PAH worsening-related hospitalization of ≥24 hours) by 76% (HR=0.24 [95% CI, 0.13-0.43]; p<0.0001 [1-sided]) compared to placebo.

1 Apr 2025

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral semaglutide) significantly reduced the risk of major adverse cardiovascular events in adults with type 2 diabetes and cardiovascular disease (CVD) and/or chronic kidney disease (CKD).

1 Apr 2025

Oral News and Research

Experimental drug NU-9 shows promise for Alzheimer's and ALS treatment

Powerful new tool promises major advances in cancer treatment

Beckman Coulter Life Sciences launches safer, Next-Generation Basophil Activation Test to improve, expedite allergy research

New quantum technology set to revolutionize gastrointestinal cancer detection and treatment

Diet and exercise habits in your 60s linked to lower fracture and heart death risk

Breakthrough protein offers new hope for pulmonary sarcoidosis treatment

Research uncovers root cause of gland damage in Sjögren's syndrome

New approach to combat influenza and herpes with bean-based gum

Innovative oral vaccine strategy combats intestinal pathogens

Hormonal contraceptives linked to higher postpartum depression risk

Rutgers researchers develop promising new oral antiviral for COVID-19

Sweetener saccharin revives old antibiotics by breaking bacterial defences

Gut bacteria may reduce the effectiveness of common medications

New data on use of EndoZip™ to treat obese patients be presented at leading global medical conferences

Gut microbiome interventions could stop type 1 diabetes in its tracks

WHO releases first reports on shortages in fungal disease treatments and diagnostics

Study identifies key predictor of stroke and dementia

Common medicines contain hidden gluten and soy, study finds

WINREVAIR™ (sotatercept-csrk) reduced the risk of a composite of all-cause death, lung transplantation and hospitalization for pulmonary arterial hypertension (PAH) by 76% compared to placebo in the phase 3 ZENITH trial

Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News